Novabay sinks on NVC-422 phase II torpedo in viral conjunctivitis
By Marie Powers
Thursday, August 21, 2014
Shares of Novabay Pharmaceuticals Inc. (NYSE MKT:NBY) plunged 44 percent, to a one-year low of 69 cents, Wednesday morning after the company reported that its NVC-422 (auriclosene) ophthalmic formulation failed to meet the primary and secondary endpoints in a phase II study in patients with adenoviral conjunctivitis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.